Hypovolemia caused by acute blood loss, in cases where the use of only crystalloids is considered insufficient.
Out of stock
Composition Refortan 130
The main active ingredients: hydroxyethyl starch, 60 mg in 1 ml of the drug.
Auxiliary components are: water for injection.
It is produced in the form of a solution for infusion. Produced in 250 ml bottles.
Pharmacological properties Refortan 130
This pharmaceutical agent belongs to the group of drugs – blood substitutes and perfusion substances.
It is used as a colloidal substitute for blood plasma volumes. The main component is hydroxyethyl starch.
After the application of this isooncotic solution, an increase in the intravascular volume of plasma content in the blood occurs, and the increase is proportional to the volume of the drug administered.
The duration of the effect of increasing plasma volume depends on various factors, including the amount of molecular weight and, to a greater extent, molar substitution.
This drug is capable of causing a decrease in hematocrit and increases the level of viscosity of the plasma component of the blood. Causes a decrease in platelet aggregation and prevents erythrocyte aggregation. Activates the transfer of water into blood from body tissues.
After the drug is administered, its effect continues for at least six hours in a row, circulating for a long time in the bloodstream.
Indications Refortan 130
It is used to eliminate hypovolemia (decrease in the volume of circulating blood) caused by acute blood loss.
Usually used in cases where the use of crystalloids alone is insufficient.
The drug in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or to one of the auxiliary components.
- hyperhydration, including pulmonary edema;
- renal failure, oliguria, anuria;
- intracranial bleeding, sepsis, burns;
- severe hypernatremia or severe hyperchloremia, hypervolemia;
- severe liver dysfunctions;
- congestive heart failure.
Application during pregnancy and lactation
It is permissible to use this drug in the treatment of pregnant women in cases of urgent need.
If it is necessary to administer the drug during breastfeeding, then during treatment, lactation should be suspended.
Method of administration and dosage
This drug is administered intravenously, in doses as low as possible with the greatest effectiveness, for the shortest possible period of time. The dose depends on the amount of blood loss.
During treatment, hemodynamics are continuously monitored in order to stop the administration as soon as its level returns to normal.
The first 10-20 ml of the drug is injected slowly in order to timely detect and prevent the development of a possible anaphylactic reaction.
Usually, in case of shock blood loss, 20 ml of the drug is injected per 1 kg of body weight, per hour. For life-threatening blood loss, up to 500 ml is administered manually (no more than 50 ml per 1 kg of body weight per day).
When infusing, it is necessary to remove the air from the container as much as possible.
In case of impaired renal or liver function, blood coagulation disorders, special care should be taken and the electrolyte content should be controlled.
Overdose can cause hypervolemia. With this development of events, it is necessary to immediately stop the infusion of the drug, if necessary, use diuretics.
In some cases, there may be some side effects in the form of:
- decreased hematocrit and decreased plasma protein concentration as a result of hemodilution;
- possible lengthening of the period of blood coagulation;
- anaphylactic shock, angioedema, allergic urticaria, hypotension, dyspnea, bronchospasm, tachycardia, arterial hypertension;
- increased serum alpha-amylase concentrations.
Repeated infusions over several days may cause a rash (may appear several weeks after the end of therapy).
Storage conditions and periods
The shelf life is up to 5 years.
No special storage conditions are required.